Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
In development
Reference number: GID-TA11498
Expected publication date:
This appraisal will be paused at the request of the company until NICE has the power to apply the new cost-effectiveness threshold. NICE anticipates that its cost-effectiveness threshold will increase in April 2026 and we will provide a further update to stakeholders at that time. More information about changes to NICE’s cost-effectiveness thresholds can be found here: https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed